Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

WARREN, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, announced in January 2025, it received $2 million on non-dilutive grant funding from KRHP LLC (“Grantor”) with an additional $8 million to be contributed contingent on the Grantor’s review of the Company’s activities. Tevogen Bio is pleased to announce it will receive the remaining $8 million in funding from the Grantor prior to the end of the current fiscal quarter based on the Grantor’s evaluation of the Company’s progress, particularly in Tevogen Bio’s artificial intelligence effort, Tevogen.AI. This $8 million grant, similar to the initial grant amount, is not dilutive to existing Tevogen Bio shareholders.

Read more at globenewswire.com